_{[News Viscovery]}

Vienna / Austria, 11 August 2022 Back to work / Back to school offer: -25% Vacation time is slowly ending. But maybe we can sweeten your start into a new work year.

Viscovery is pleased to offer a one-time 25% discount on all Viscovery SOMine 7 licenses for orders until August 31st, 2022.

Do you have customer data you are trying to fully utilize and turn to benefits?

Or are you searching for new methods to analyze and publish your research data?

Maybe you are supervising students and want to give them a tool to really explore and learn from their data to write compelling theses?

Do it by taking advantage of Viscovery SOMine.

You want to analyze, explore and visualize your data? Cluster it, calculate test statistics, make statistical analyses? Build, evaluate and implement classification and numerical prediction models? Viscovery SOMine is a modular data mining suite, which can be licensed suitably to your individual needs.

Take the opportunity - order now and save your budget!

Term licenses can easily be acquired in our online shop (viscovery.net/somine).

For network licenses and perpetual licenses please contact office@viscovery.net.

_{[News Viscovery]}

Munich (DE) / Vienna (AT), 7 June 2022 Viscovery and Biomax are introducing an analysis pipeline for longitudinal brain morphometry studies

Together with our colleagues from Biomax Informatics, we published the article Automated High-Definition MRI Processing Routine Robustly Detects Longitudinal Morphometry Changes in Alzheimer’s Disease Patients in Frontiers in Aging Neuroscience.

In this article a profound analysis pipeline for longitudinal MRI studies is proposed. It uses state-of-the-art methods for neuro-imaging, segmentation and statistical assessments. A case study with Alzheimer’s disease patients and a control group of age-related cognitively normal subjects from the ADNI-3 study was conducted to test the pipeline which was fully implemented in Biomax’ neuro-imaging solution NICARA.

Find the full open access article at www.frontiersin.org.

_{[News Viscovery]}

Horn (NL) / Vienna (AT), 21 February 2022 Viscovery profiles outcomes to bronchodilator therapy

Together with Maud Koopman and her colleagues from our long term customer CIRO+, we published the article Differential Outcomes Following 4 Weeks of Aclidinium/Formoterol in Patients with COPD: A Reanalysis of the ACTIVATE Study in the International Journal of Chronic Obstructive Pulmonary Disease.

The ACTIVATE study is a randomized, double-blind and placebo-controlled study investigating the effects of aclidinium bromide / formoterol fumarate bronchodilator therapy on lung hyperinflation and physical exercise capabilities. The outcome data on lung function and physical exercises were clustered with Viscovery SOMine to find typical outcome profiles and assess the impact of bronchodilator therapy.

Find the full open access article at www.dovepress.com

_{[News Viscovery]}

Horn (NL) / Vienna (AT), 17 February 2022 Finding response predictors with Viscovery SOMine Together with Ingrid Augustin and her colleagues from our long term customer CIRO+, we published the article Multidimensional outcome assessment of pulmonary rehabilitation in traits-based clusters of COPD patients in PLOS ONE.

Building on the previous work with Ingrid Augustin from 2020, we clustered the multidimensional outcome parameters and compared this new clustering to the comprehensive model from 2020 which incorporates pulmonary and extra-pulmonary traits at base assessment. The comprehensive base assessment model has distinct predictive power to forecast probable response patterns.

Find the full open access article at journals.plos.org.